Security
Bolt Biotherapeutics, Inc. Common Stock · BOLT
BOLTNASDAQCommon stockCurrentCIK 1641281Updated Nov 14, 2026
Name history
Bolt Therapeutics, Inc. · through May 7, 2015
BOLT price & chart
Loading TradingView…
NASDAQ:BOLT on TradingView ↗About the company
Bolt Biotherapeutics is a clinical-stage biotechnology company pioneering a new generation of half-life-extended multispecific antibodies designed to deliver best-in-disease therapies. Through the proprietary INSPIRE platform it acquired from Prana Therapies, the company combines complementary therapeutic mechanisms in fully IgG-based molecules designed for differentiated efficacy, extended exposure, and convenient dosing.
In the news
Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update ↗
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G/A - filed by RENAISSANCE TECHNOLOGIES LLC regarding Bolt Biotherapeutics, Inc.
4 filing
3 filing
Show 5 more recent filings
Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Unregistered Sales of Equity Securities · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure · Other Events
Items 1.01, 1.02, 2.01, 3.02, 5.02, 5.03, 7.01, 8.01, 9.01
Entry into a Material Definitive Agreement
Items 1.01
4 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 65,053,000Source | 109,334,000Source | 40,344,000Source | 75,499,000Source | 124,176,000Source | 48,027,000Source | 85,862,000Source | 142,892,000Source | 56,748,000Source | 99,632,000Source | 159,784,000Source | 227,807,000Source |
| Property, Plant and Equipment, NetUSD | 1,500,000Source | 3,565,000Source | 571,000Source | 1,718,000Source | 4,079,000Source | 1,042,000Source | 2,065,000Source | 4,499,000Source | 1,245,000Source | 3,139,000Source | 4,957,000Source | 6,453,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 17,753,000Source | 9,366,000Source | 12,860,000Source | 9,601,000Source | 6,202,000Source | 11,609,000Source | 8,391,000Source | 4,262,000Source | 11,703,000Source | 7,205,000Source | 10,810,000Source | 9,244,000Source |
| Assets, CurrentUSD | 35,606,000Source | 57,147,000Source | 20,564,000Source | 38,336,000Source | 76,631,000Source | 25,752,000Source | 42,509,000Source | 95,055,000Source | 30,260,000Source | 50,814,000Source | 105,708,000Source | 172,746,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,912,000Source | 2,557,000Source | 2,766,000Source | 2,783,000Source | 2,934,000Source | 2,660,000Source | 2,887,000Source | 3,705,000Source | 2,555,000Source | 2,707,000Source | 3,519,000Source | 3,858,000Source |
| Operating Lease, Right-of-Use AssetUSD | 19,881,000Source | 16,756,000Source | 17,075,000Source | 20,517,000Source | 17,559,000Source | 18,564,000Source | 21,141,000Source | 18,347,000Source | 19,230,000Source | 21,756,000Source | 19,120,000Source | 22,072,000Source |
| Other Assets, NoncurrentUSD | 179,000Source | 287,000Source | 87,000Source | 222,000Source | 308,000Source | 112,000Source | 51,000Source | 1,765,000Source | 138,000Source | 62,000Source | 1,821,000Source | 1,028,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 32,952,000Source | 37,303,000Source | 27,704,000Source | 36,657,000Source | 38,316,000Source | 28,205,000Source | 39,052,000Source | 38,733,000Source | 30,243,000Source | 42,434,000Source | 47,043,000Source | 56,301,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | 0Source | — | — | 0Source | — | — | 0Source | — | — | 0Source | — |
| Common Stock, Value, IssuedUSD | 0Source | 1,000Source | 0Source | 0Source | 1,000Source | 0Source | 0Source | 1,000Source | 0Source | 0Source | 1,000Source | 0Source |
| Retained Earnings (Accumulated Deficit)USD | -454,148,000Source | -411,467,000Source | -475,743,000Source | -447,004,000Source | -396,291,000Source | -468,023,000Source | -438,443,000Source | -375,096,000Source | -460,779,000Source | -427,403,000Source | -364,285,000Source | -295,088,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -10,000Source | 205,000Source | -44,000Source | -6,000Source | -44,000Source | -11,000Source | 40,000Source | -36,000Source | -21,000Source | 97,000Source | 37,000Source | -919,000Source |
| Stockholders' Equity Attributable to ParentUSD | 32,101,000Source | 72,031,000Source | 12,640,000Source | 38,842,000Source | 85,860,000Source | 19,822,000Source | 46,810,000Source | 104,159,000Source | 26,505,000Source | 57,198,000Source | 112,741,000Source | 171,506,000Source |
| Additional Paid in Capital, Common StockUSD | 486,259,000Source | 483,292,000Source | 488,427,000Source | 485,852,000Source | 482,194,000Source | 487,856,000Source | 485,213,000Source | 479,290,000Source | 487,305,000Source | 484,504,000Source | 476,988,000Source | 467,513,000Source |
| Liabilities and EquityUSD | 65,053,000Source | 109,334,000Source | 40,344,000Source | 75,499,000Source | 124,176,000Source | 48,027,000Source | 85,862,000Source | 142,892,000Source | 56,748,000Source | 99,632,000Source | 159,784,000Source | 227,807,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 9,966,000Source | 18,083,000Source | 7,867,000Source | 12,310,000Source | 17,900,000Source | 7,343,000Source | 13,562,000Source | 16,723,000Source | 8,435,000Source | 15,856,000Source | 20,456,000Source | 23,118,000Source |
| Operating Lease, Liability, CurrentUSD | 2,700,000Source | 2,824,000Source | 3,091,000Source | 2,559,000Source | 2,995,000Source | 2,956,000Source | 2,400,000Source | 2,887,000Source | 2,826,000Source | 2,251,000Source | 2,782,000Source | 2,391,000Source |
| Accounts Payable, CurrentUSD | 1,518,000Source | 1,482,000Source | 868,000Source | 1,852,000Source | 2,627,000Source | 1,736,000Source | 1,534,000Source | 2,219,000Source | 1,443,000Source | 1,507,000Source | 2,987,000Source | 3,594,000Source |
| Operating Lease, Liability, NoncurrentUSD | 20,889,000Source | 15,353,000Source | 18,533,000Source | 21,624,000Source | 15,896,000Source | 19,352,000Source | 22,309,000Source | 16,680,000Source | 20,132,000Source | 22,958,000Source | 17,437,000Source | 20,220,000Source |
| Other Liabilities, NoncurrentUSD | 133,000Source | 0Source | 132,000Source | 133,000Source | 0Source | 158,000Source | 132,000Source | 0Source | 132,000Source | 0Source | 43,000Source | 42,000Source |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 38,800,000Source | 84,400,000Source | 18,100,000Source | 48,500,000Source | 97,500,000Source | 23,900,000Source | 58,000,000Source | 112,800,000Source | 31,800,000Source | 70,200,000Source | 128,600,000Source | 192,800,000Source |
| Deferred Revenue, CurrentUSD | 1,909,000Source | 1,971,000Source | 819,000Source | 2,512,000Source | 2,024,000Source | 630,000Source | 3,083,000Source | 1,907,000Source | 449,000Source | 3,015,000Source | 2,201,000Source | 1,993,000Source |
| Deferred Revenue, NoncurrentUSD | 1,964,000Source | 3,867,000Source | 1,172,000Source | 2,590,000Source | 4,520,000Source | 1,352,000Source | 3,049,000Source | 5,330,000Source | 1,544,000Source | 3,620,000Source | 9,107,000Source | 12,921,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 5,656,000Source | 6,509,000Source | 5,983,000Source | 7,058,000Source |
| Short-term InvestmentsUSD | 14,157,000Source | 44,432,000Source | 4,738,000Source | 25,168,000Source | 67,495,000Source | 11,283,000Source | 30,447,000Source | 87,088,000Source | 15,802,000Source | 40,118,000Source | 91,379,000Source | 159,644,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -7,244,000Source | -11,040,000Source | -33,376,000Source | -63,118,000Source | -69,197,000Source | -88,098,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 203,000Source | 399,000Source | 1,291,000Source | 1,781,000Source | 1,854,000Source | 1,666,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 545,000Source | 709,000Source | 2,782,000Source | 7,407,000Source | 9,223,000Source | 9,576,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -8,023,000Source | -13,365,000Source | -39,850,000Source | -61,289,000Source | -69,525,000Source | -76,504,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 7,923,000Source | 14,551,000Source | 44,302,000Source | 57,576,000Source | 71,038,000Source | 57,862,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 72,000Source | 41,000Source | 206,000Source | 1,953,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 6,000Source | 0Source | 19,000Source | 108,000Source | 253,000Source | 503,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -94,000Source | 1,186,000Source | 4,471,000Source | -3,605,000Source | 1,766,000Source | -18,139,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 19,518,000Source | 11,139,000Source | 14,598,000Source | 11,366,000Source | 13,347,000Source | 10,156,000Source | 13,441,000Source | 8,970,000Source | 12,575,000Source | 10,809,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 407,000Source | 1,098,000Source | 552,000Source | 625,000Source | 545,000Source | 709,000Source | 2,782,000Source | 7,407,000Source | 9,223,000Source | 9,576,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 38,800,000Source | 84,400,000Source | 18,100,000Source | 48,500,000Source | 23,900,000Source | 58,000,000Source | 31,800,000Source | 70,200,000Source | 128,600,000Source | 192,800,000Source |
| DepreciationUSD | — | — | 300,000Source | 500,000Source | 200,000Source | 300,000Source | 200,000Source | 400,000Source | 1,300,000Source | 1,800,000Source | 1,900,000Source | 1,700,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | 288,000Source | 70,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 3,337,000Source | 3,799,000Source | 2,422,000Source | 3,516,000Source | 2,798,000Source | 3,825,000Source | 13,795,000Source | 18,457,000Source | 22,530,000Source | 22,927,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,144,000Source | -15,176,000Source | -7,720,000Source | -8,561,000Source | -7,244,000Source | -11,040,000Source | -33,376,000Source | -63,118,000Source | -69,197,000Source | -88,098,000Source |
| Nonoperating Income (Expense)USD | — | — | 559,000Source | 1,267,000Source | 654,000Source | 649,000Source | 357,000Source | 1,075,000Source | 2,737,000Source | 9,930,000Source | 6,999,000Source | 2,223,000Source |
| Operating ExpensesUSD | — | — | 9,872,000Source | 17,584,000Source | 8,379,000Source | 11,014,000Source | 7,627,000Source | 13,337,000Source | 43,808,000Source | 80,738,000Source | 84,072,000Source | 96,050,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 6,000Source | 0Source | 19,000Source | 108,000Source | 253,000Source | 503,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 2,169,000Source | 1,141,000Source | 5,000Source | 1,804,000Source | 26,000Source | 1,222,000Source | 7,695,000Source | 7,690,000Source | 7,876,000Source | 5,729,000Source |
| Operating Income (Loss)USD | — | — | -7,703,000Source | -16,443,000Source | -8,374,000Source | -9,210,000Source | -7,601,000Source | -12,115,000Source | -36,113,000Source | -73,048,000Source | -76,196,000Source | -90,321,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -33,376,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,144,000Source | -15,176,000Source | -7,720,000Source | -8,561,000Source | -7,244,000Source | -11,040,000Source | -33,376,000Source | -63,118,000Source | -69,197,000Source | -88,098,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -3.72Source | -7.93Source | -4.57Source | -4.46Source | -4.31Source | -5.76Source | -17.85Source | -1.65Source | -1.83Source | -2.36Source |
| Earnings Per Share, DilutedUSD per share | — | — | -3.72Source | -7.93Source | -4.57Source | -4.46Source | -4.31Source | -5.76Source | -17.85Source | -1.65Source | -1.83Source | -2.36Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 1,919,441Source | 1,912,554Source | 1,690,529Source | 1,917,629Source | 1,680,445Source | 1,916,943Source | 1,869,924Source | 38,183,931Source | 37,811,984Source | 37,358,425Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 1,919,441Source | 1,912,554Source | 1,690,529Source | 1,917,629Source | 1,680,445Source | 1,916,943Source | 1,869,924Source | 38,183,931Source | 37,811,984Source | 37,358,425Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 3,337,000Source | 3,799,000Source | 2,422,000Source | 3,516,000Source | 2,798,000Source | 3,825,000Source | 13,795,000Source | 18,457,000Source | 22,530,000Source | 22,927,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -31,885,000Source | — | — | — |
| Investment Income, NetUSD | — | — | 477,000Source | 1,267,000Source | 178,000Source | 599,000Source | 276,000Source | 1,053,000Source | 2,496,000Source | 5,255,000Source | 6,999,000Source | 2,223,000Source |
| Labor and Related ExpenseUSD | — | — | 2,896,000Source | 4,926,000Source | 1,932,000Source | 3,980,000Source | 2,211,000Source | 4,687,000Source | 13,544,000Source | 23,936,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 559,000Source | 1,267,000Source | 654,000Source | 649,000Source | 357,000Source | 1,075,000Source | 2,737,000Source | 9,930,000Source | 6,999,000Source | 2,223,000Source |
| Operating ExpensesUSD | — | — | 9,872,000Source | 17,584,000Source | 8,379,000Source | 11,014,000Source | 7,627,000Source | 13,337,000Source | 43,808,000Source | 80,738,000Source | 84,072,000Source | 96,050,000Source |
| Other ExpensesUSD | — | — | 289,000Source | 440,000Source | 171,000Source | 348,000Source | 203,000Source | 399,000Source | — | 2,266,000Source | — | — |
| Other IncomeUSD | — | — | 82,000Source | 0Source | 476,000Source | 50,000Source | 81,000Source | 22,000Source | 241,000Source | 4,675,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 6,535,000Source | 13,785,000Source | 5,149,000Source | 7,498,000Source | 4,829,000Source | 9,512,000Source | 28,533,000Source | 57,469,000Source | 61,542,000Source | 73,123,000Source |
| Other General and Administrative Expense | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
Filing attachments
bolt-ex99_1.htm · 8-K · 2026-11-12
Exhibit 99.1 Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Completed acquisition of Prana Therapies and $120 million concurrent private placement financing, establishing PRA-216 and the INSPIRE-built pipeline as Bolt’s primary development focus • Initiated Phase 2 studies with PRA-216, a half-life-extended IL-4Rα/TSLP bispecific, in asthma, atopic dermatitis and chronic obstructive pulmonary disease with initial data expected in 2Q 2027 • Re…
Read attachment ↗bolt-ex99_1.htm · 8-K · 2026-10-23
Exhibit 99.1 Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications • Transactions position the company to advance Prana’s pipeline of next-generation, half-life-extended multispecific antibodies enabled by its proprietary INSPIRE platform • PRA-216 is a novel IL-4Rα/TSLP bispecific antibody currently in Phase 2 development for asthma, COPD, and atopic dermatitis, with a Pha…
Read attachment ↗bolt-ex99_2.htm · 8-K · 2026-10-23
Company Transaction & Overview Bolt Biotherapeutics and Prana Therapies October 23, 2026 Disclosures This Presentation has been prepared by Bolt Biotherapeutics, Inc. ("Bolt") and Prana Therapies, Inc. ("Prana" and, together with Bolt and each of Bolt's and Prana’s subsidiaries, the "combined company") and contains information pertaining to the business and operations of the combined company. The information contained in this Presentation: (a) is provided as at the date hereof, is subject to ch…
Read attachment ↗bolt-ex99_1.htm · 8-K · 2026-08-11
EX-99.1 2 bolt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update • First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 results • Cash balance of $18.1 million as of June 30, 2026 anticipated to fund operations into 1Q 2027 REDWOOD CITY, CA, August 11, 2026 - Bolt Biotherapeutics (Nasdaq: BOLT), a clinic…
Read attachment ↗bolt-ex99_1.htm · 8-K · 2026-05-12
EX-99.1 2 bolt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update • First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 • Cash balance of $23.9 million as of March 31, 2026 anticipated to fund operations into 2027, including completion of the dose escalation portion of the ongoing BDC-4182 Phase 1/2 study REDWOOD CITY, CA, May 1…
Read attachment ↗bolt-ex99_1.htm · 8-K · 2026-03-12
EX-99.1 2 bolt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update • First-in-class immune-stimulating antibody conjugate BDC-4182 in Phase 1 dose escalation study, initial clinical data expected in 3Q 2026 • Cash balance of $31.8 million as of December 31, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY, CA, Mar. 12, 2026 - Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-sta…
Read attachment ↗